Format

Send to

Choose Destination
Medicine (Baltimore). 2020 Jan;99(1):e18524. doi: 10.1097/MD.0000000000018524.

Drug utilization in the Maastricht Study: A comparison with nationwide data.

Author information

1
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center.
2
School for Cardiovascular Diseases (CARIM), Maastricht University, Maastricht.
3
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht.
4
School for nutrition, and translational research in metabolism (NUTRIM), Maastricht University.
5
Department of Epidemiology, Maastricht University.
6
School for Public Health and Primary Care (CAPHRI), Maastricht University.
7
Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center +, Maastricht.
8
Department of Pharmacy, Sint Maartenskliniek.
9
Department of Pharmacy, Radboud University Medical Center, Nijmegen.
10
Department of Clinical Pharmacy, Amphia Hospital, Breda.
11
Department of Internal Medicine, Maastricht University Medical Center +, Maastricht, The Netherlands.
12
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Eidgenossische Technische Hochschule Zurich, Zurich, Switzerland.

Abstract

Within the southern region of the Netherlands, the Maastricht Study is an on-going observational prospective population-based cohort study that focuses on the etiology of Type 2 diabetes mellitus (T2DM). Representativeness of the participating population is a crucial but often an unknown factor in population-based cohort studies such as the Maastricht Study. We therefore aimed to assess the representativeness of the study population by comparing drug utilization of the participants of the Maastricht Study with the general population of the Netherlands.Since T2DM patients were oversampled in this study, a sampling method was applied in order to ensure a similar distribution of T2DM over the study population. Drug use in the study population was compared with drug use in the population of the Netherlands, using a Z-test to compare 2 independent proportions.In general, drug use in the study was similar compared with national data. However, in the age group 65 to 74 years total drug use was lower in the study population (833/1000 persons) versus nationwide data (882/1000 persons). The use of pulmonary medications was lower (104/1000 persons vs 141/1000 persons) and the use of hypnotics/anxiolytics was higher (90/1000 persons vs 36/1000 persons) in the Maastricht Study as compared with national data.Drug use in the Maastricht Study population is largely comparable to that in the total Dutch population aged 45 to 74. Therefore, data on drug use by participants in the Maastricht Study can be used to perform studies assessing outcomes associated with drug use.

PMID:
31895787
DOI:
10.1097/MD.0000000000018524
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center